我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

国产与进口氯吡格雷对行介入治疗的不稳定型心绞痛患者抗血小板作用效果比较(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第4期
页码:
464-466
栏目:
临床研究
出版日期:
2008-08-20

文章信息/Info

Title:
Comparison of effect of clopidogrel made in China and imported on antiplatelet in unstable angina pectoris patients undergoing intervention
作者:
张环1; 赵志敬2; 李伟杰2; 辛渭川1
1.西安市中心医院心脏内科，陕西 西安 710004； 2.第四军医大学西京医院心脏内科，陕西 西安 710032
Author(s):
ZHANG Huan1;  ZHAO Zhijing2;  LI Weijie2;  XIN Weichuan1
1.Department of Cardiology, Xi’an Central Hospital, Xi’an 710004, Shaanxi, China; 2.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
关键词:
不稳定型心绞痛; 血小板; 氯吡格雷; α颗粒膜蛋白; 血栓素B2; 6酮前列腺素F1α
Keywords:
unstable angina pectoris;  platelet;  clopidogrel;  α-granule membrane protein;  thromboxane B2;  6ketoprostaglandin F1α
分类号:
R973.2
DOI:
-
文献标识码:
A
摘要:
目的 观察国产与进口氯吡格雷对行介入治疗的不稳定型心绞痛（UAP）患者的抗血小板作用效果。方法 UAP患者75 例，入院后均拟行选择性冠状动脉造影检查及（或）经皮冠状动脉成形术加支架术。随机分为两组，国产药组服用国产氯吡格雷（商品名泰嘉，深圳信立泰药业公司生产，每片25 mg）；进口药组服用进口氯吡格雷（商品名波立维，赛诺菲公司生产，每片75 mg）。两组患者均在给予阿司匹林300 mg/d的基础上，第1天给予氯吡格雷负荷剂量300 mg，从第2天起给予氯吡格雷常规剂量75 mg/d，所有患者在服药24 h之后行介入性诊治。分别在服药前、服药后2，4，6 h和24 h取外周静脉血，采用放射免疫法分析法检测两组患者血浆中α颗粒膜蛋白(αgranule membrane protein，GMP140)、血栓素B2(thromboxane B2，TXB2)和6酮前列腺素F1α(6ketoprostaglandin F1α，6ketoPGF1α)的水平。结果 两组服药后2，4，6和24 h血浆GMP140，TXB2，6ketoPGF1α均较服药前显著降低(P<005)。两组间比较，仅在服药后2 h 国产药组血浆GMP140，TXB2均高于进口药组(P<005)；4 h之后两组血浆GMP140，TXB2，6ketoPGF1α均无显著性差异。结论 氯吡格雷起效迅速，首剂负荷剂量300 mg服药后2 h即可有效抑制血小板活性，国产药组仅2 h稍逊于进口药组，4 h后两组药物的抗血小板作用无显著性差异。
Abstract:
AIM To observe the effect of clopidogrel made in China and imported on antiplatelet in unstable angina pectoris（UAP） patients undergoing intervention. METHODS Seventyfive patients with UAP were randomly divided into clopidogrel made in China group (Taijia group ) and imported group (polivex group). Both groups were given Taijia or polivex 300 mg in the first day and 75 mg/d from second day respectively. At the same time, both groups took Aspirin 300 mg/d. 24 hours after taking the medicine, intervention therapy was performed in all the patients. Venous blood samples were taken before taking medicine and 2 h, 4 h, 6 h and 24 h after taking medicine and the samples were analyzed for the levels of plasma GMP140, TXB2 and 6ketoPGF1α by radioimmunity. RESULTS ① 2 h, 4 h, 6 h and 24 h after taking medicine, the levels of plasma GMP140, TXB2 and 6ketoPGF1α were significantly lower than those before taking medicine in the two groups (P<005); ② 2 h after taking medicine, the levels of plasma GMP140 and TXB2 in Taijia group were higher than those in polivex group (P<005). But, 4h, 6h and 24h after taking medicine, no statistical difference was observed in the levels of plasma GMP140, TXB2 and 6ketoPGF1α between Taijia group and polivex group. CONCLUSION At 2 h after taken clopidogrel, a loading dose of 300 mg can effectively inhibit the activation of platelets. There is no statistical difference in the effect of antiplatelet between Taijia and polivex 4 h after taking medicine.

参考文献/References

［1］ Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) ［J］. J Am Coll Cardiol, 2001, 37(8):2215-2239.

［2］ Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention［J］. JAMA, 2002, 288(19):2411-2420.

［3］ Geiger J, Brich J, HonigLiedl P, et al. Specific impairment of human platelet P2Y(AC)ADP receptor mediated signaling by the antiplatelet drug clopidogrel［J］. Arterioscler Thromb Vasc Biol, 1999, 19(8):2007-2011.

［4］ Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans［J］. Circulation, 2000, 101(24):2823-2828.

［5］ Sidney C, Smith SC Jr, Ted E, et al. ACC/AHA/SCA I 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA /SCA I Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)［J］ . J Am Coll Cardiol, 2006, 47(1):1-121.

［6］ 吴志坚. 加用氯吡格雷治疗不稳定型心绞痛的临床观察［J］. 心脏杂志, 2006, 18(1):112.

［7］ 朱梅，贾国良. 氯吡格雷对不稳定型心绞痛患者血小板功能的影响［J］. 心脏杂志, 2003, 15(5):425-427.

［8］ Cutlip DE, Bain DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials［J］. Circulation, 2001, 103(15)：1967-1971.

［9］ Cadroy Y, Harker LA. Platelets, thrombosis and antithrombotic therapies［M］// Antonaccio M. Cardiovascular pharmacology. Third ed. New York: Raven Press, 1990:515-539.

备注/Memo

备注/Memo:
收稿日期：2007-10-23.作者简介：张环，主治医师，硕士Email:zhaozhj@fmmu.edu.cn
更新日期/Last Update: